Current Tumor Suppressor News and Events

Current Tumor Suppressor News and Events, Tumor Suppressor News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Scientists model a peculiar type of breast cancer
Scientists led by EPFL have developed a breakthrough in vivo model for invasive lobular carcinoma, a serious yet understudied type of breast cancer. The work will open up previously inaccessible study of the tumor's biology and help discover new therapies. (2021-02-22)

NYUAD researchers develop high throughput paper-based arrays of 3D tumor models
By engineering common filter papers, similar to coffee filters, a team of NYU Abu Dhabi researchers have created high throughput arrays of miniaturized 3D tumor models to replicate key aspects of tumor physiology, which are absent in traditional drug testing platforms. With the new paper-based technology, the formed tumor models can be safely cryopreserved and stored for prolonged periods for on-demand drug testing use. (2021-02-22)

Improving immunotherapies for blood cancers: real-time exploration in the tumor
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called ''immunotherapies.'' But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? Using innovative in vivo imaging approaches, scientists from the Institut Pasteur and Inserm visualized in real time how anti-CD20 antibodies, used to treat B-cell lymphoma, guide the immune system to attack tumor cells. (2021-02-21)

Good cop, bad cop
Serendipitous observation leads to novel insight into how cancer-immune crosstalk can either promote or suppress tumour growth. Ultimately, this study's results may help develop novel cancer therapies as well as an assay to select patients for immunotherapy treatment. (2021-02-19)

3D biopsies to better understand brain tumors
Researchers at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) obtained a highly accurate recreation of human glioblastoma's features using a novel 3D microscopy analysis. The study, published in the journal Acta Neuropathologica Communications, provides new information to help with the diagnose, by finding therapeutical targets and designing immunotherapeutical strategies. (2021-02-19)

Handcuffing the culprit cancer: Immunotherapy for cold tumors with trispecific antibody
The recent discovery of ''bispecific antibodies'' has led to the development of effective immunotherapies against various cancers. Researchers have constructed a protein made up of anti-CD16, -IL-15, and -CD19 motifs, specifically designed to capture CD19-positive cancer cells and redirect them to natural killer (NK) cells. This protein also enhances the proliferation, homeostasis, activation, and survival of NK cells. This concoction has shown to induce killing of cancer cells in both cell cultures and in mouse models. (2021-02-18)

Cosmetic laser may boost effectiveness of certain anti-cancer therapies
In mice treated with cancer immunotherapy, shining a cosmetic laser on a tumor boosted the therapy's effectiveness. The strategy stimulated the immune system to attack nonmutated proteins on the tumor. The findings may help investigators make cancer immunotherapy effective against currently incurable cancers. (2021-02-17)

Dr. Frederick Boop presents at the ISPN 2020 Virtual Meeting
Understanding the molecular biology of brain tumors is key to prognosis and treatment said Le Bonheur Neuroscience Institute Co-Director Frederick Boop, MD, in his presentation ''How Molecular Biology Impacts Clinical Practice'' at the International Society for Pediatric Neurosurgery (ISPN) 2020 Virtual Meeting. (2021-02-17)

Immunosuppressive cell and cytokine response linked to bone nonunion
An abnormal suppression of the immune system linked to the onset of numerous diseases has been associated with poor functional regeneration of traumatic bone injuries. The discovery could guide a path for predicting which trauma patients may are less likely to respond to treatment. (2021-02-17)

Photosynthetic bacteria-based cancer optotheranostics
Natural purple photosynthetic bacteria (PPSB) can play a key role as a highly active cancer immunotheranostics agent that uses the bio-optical-window I and II near-infrared (NIR) light. PPSB have high tumor specificity and non-pathogenicity. Active anticancer efficacy and powerful multi-functions such as NIR-I-to-NIR-II fluorescence, photothermal conversion, reactive oxygen species generation, and contrasty photoacoustic effect, can be expressed using NIR light exposure to PPSB. (2021-02-16)

Combination treatment for common glioma type shows promise in mice
Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas and found tumor regression in 60 percent of the mice treated. These encouraging results could be the first step toward developing a treatment for this type of brain cancer. (2021-02-16)

New immunotherapy target discovered for malignant brain tumors
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body's immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients. (2021-02-15)

Oncotarget: Targeting engineered cytokine with interleukin to the neovasculature of tumors
''The results suggest that this product, or similar fusion proteins featuring an N-terminal fusion in the diabody format, may deserve to be investigated in clinical trials'' (2021-02-15)

Oncotarget: Cancer stem cells and macrophages against cancer
The aim of this Oncotarget review is to define the complex crosstalk between these two cell types and to highlight potential future anti-cancer strategies (2021-02-15)

Antitumoral effects of LXR activation
Tumor cells are able to avoid the attack of the immune system through several mechanisms. For instance, these can secrete factors that turn macrophages -cells in the immune system- into dual action agents that contribute to the tumor progress and will protect it from immune body defences: these become, thus, the tumor-associated macrophages (TAMs). (2021-02-12)

Medication-based starvation of cancer cells
Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies. (2021-02-12)

Liquid biopsy for colorectal cancer could guide therapy for tumors
A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor. Such a biopsy can detect lingering disease and could serve as a guide for deciding whether a patient should undergo further treatments due to some tumor cells evading an initial attempt to eradicate the cancer. (2021-02-12)

Get a load of ZIF! Better delivery of cancer immunotherapy
An antibody loaded onto a porous metal organic framework is released by the acidic environment that surrounds tumors, avoiding the adverse effects of administering the antibody alone. (2021-02-11)

Ionic liquid uniformly delivers chemotherapy to tumors while destroying cancerous tissue
A Mayo Clinic team, led by Rahmi Oklu, M.D., Ph.D., a vascular and interventional radiologist at Mayo Clinic, in collaboration with Samir Mitragotri, Ph.D., of Harvard University, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. This discovery could solve a problem that has long plagued drug delivery to tumors. (2021-02-11)

Aggressive brain tumor mapped in genetic, molecular detail
A new study led by Washington University School of Medicine in St. Louis has revealed a detailed map of the genes, proteins, infiltrating cells and signaling pathways that play key roles in driving glioblastoma. The study, of 99 tumors from patients, is the largest and most detailed schematic of this deadly brain tumor. (2021-02-11)

SRC-3 is a novel regulator of human immune T regulatory cells
SRC-3, a prognostic marker for aggressive human breast and other cancers, also regulates human immune T regulatory cells (Tregs), which are involved in fighting cancer. (2021-02-11)

Why Black men's prostate cancer may be more responsive to immunotherapy
Black men die more often of prostate cancer yet have greater survival benefits from immunotherapy treatment. A new study discovered the reason appears to be an increase of a surprising type of immune cell in the tumor. The findings could lead to immune-based precision medicine treatment for men of all races with localized aggressive and advanced prostate cancer. (2021-02-10)

Evidence for routine brain tumor imaging is murky, but research can shed light
After treatment, medical staff use routine brain scans to monitor progress in brain tumor patients. However, how often such scans should occur is unclear. A Position Statement from a large group of UK experts highlights that the evidence behind current scanning routines is weak. The article highlights numerous ways that researchers can gather evidence to improve scanning routines so that they are most effective and do not interfere with patient quality of life. (2021-02-09)

Radiation vulnerability
Exposure to radiation can wreak indiscriminate havoc on cells, tissues, and organs. Curiously, however, some tissues are more vulnerable to radiation damage than others. A new study now finds that cellular survival after radiation exposure depends on behavior of the tumor-suppressor protein p53 over time. In vulnerable tissues, p53 levels go up and remain high, leading to cell death. In tissues that tend to survive radiation damage, p53 levels oscillate up and down. (2021-02-09)

Known tumour suppressor gene found essential for development, regeneration&stress-response
- Experiments carried out in the Drosophila fly have led to the identification of the headcase (hdc) gene as pivotal for adult progenitor cells, allowing them to undergo metamorphosis and give rise to adult tissue structures. - The study by IRB Barcelona's Development and Morphogenesis in Drosophila lab has been published in PLOS Genetics. (2021-02-09)

Drug is promising against pancreatic and breast cancers
The drug is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular and Molecular Gastroenterology and Hepatology. A second study, published in the Journal of Experimental Medicine, shows the drug is also effective against triple-negative breast cancer, a fast-growing and hard-to-treat type of breast cancer that carries a poor prognosis. Clinical trials are set to begin in 2021. (2021-02-09)

Technion researchers discover new pathway for attacking cancer cells
The folate cycle is a process essential to DNA and RNA production. As a result, it is highly important to both cancer cells and healthy cells. Because DNA production is a critical stage in cell division, and thus in tumor growth, the folate cycle is a common target for chemotherapy. However, for the very same reason, there are significant side effects to attacking it. (2021-02-05)

How elephants evolved to become big and cancer-resistant
In this new study, 'We explored how elephants and their living and extinct relatives evolved to be cancer-resistant,' says University at Buffalo biologist Vincent Lynch. He adds, regarding the findings, 'Elephants have lots and lots and lots of extra copies of tumor suppressor genes, and they all contribute probably a little bit to cancer resistance.' (2021-02-04)

Using Artificial Intelligence to prevent harm caused by immunotherapy
Until recently, researchers and oncologists had placed these lung cancer patients into two broad categories: those who would benefit from immunotherapy, and those who likely would not. Now, researchers at Case Western Reserve University, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy. (2021-02-04)

How blood and lymph vessels remain separated after development
Researchers in Japan have clarified the mechanism by which blood and lymphatic vessels remain separated after development. The characteristics and structures of these two vessel types are very similar, and how they maintain separation has remained unexplained for many years. In this study, researchers found that the molecule Folliculin (FLCN) in vascular endothelial cells acts as a gatekeeper to maintain separation between the two. (2021-02-04)

Moffitt researchers discover mechanism that regulates anti-tumor activity of immune cells
In a new article published in Nature, Moffitt Cancer Center researchers demonstrate why some ovarian cancer patients evolve better than others and suggest possible approaches to improve patient outcomes. (2021-02-03)

"Genetic SD-card": Scientists obtained new methods to improve the genome editing system
Researchers take a step in the development of genome editing technology. Currently it is possible to deliver genetic material of different sizes and structures to organs and tissues. This is the key to eliminating DNA defects and treating more patients. (2021-02-02)

Yale researchers develop injection to treat skin cancer
Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery. (2021-02-02)

Mathematical method developed to predict cancer and drug-specific immunotherapy efficacy
Houston Methodist researchers have developed a mathematical model to predict how specific cancers will respond to immunotherapy treatments, thus enhancing chances for successful treatments from a wide variety of cancer-immunotherapy drug combinations. The results were recently published in Nature Biomedical Engineering in collaboration with researchers at MD Anderson Cancer Center. (2021-02-01)

Radiation Oncology trials using PET with FDG uptake among NSCLC patients
Two radiation oncology trials presented at the IALSC World Conference on Lung Cancer Singapore highlight how some researchers are exploring use of higher radiation boost doses to only PET-positive regions in locally-advanced non-small cell lung cancer (NSCLC). A previous large RTOG phase III trial revealed that the unform delivery of a high dose to the entire tumor led to poorer survival. (2021-01-29)

How a little-known glycoprotein blocks a cancer cell's immune response
Researchers uncovered how stanniocalcin-1, or STC1, works inside a tumor cell to block a cellular ''eat-me'' signal that typically triggers the immune system to produce T cells to fight the tumor. The findings provide a potential target to improve immune responses to cancer. (2021-01-28)

Toho university scientists find new mechanism to keep cell death pathway suppressed
A research group led by Prof. Hiroyasu Nakano at the Department of Biochemistry, Toho University Faculty of Medicine, identified Mind bomb-2 (MIB2) as an enzyme that ubiquitinates and modifies the protein cFLIP, which plays a central role in suppressing cell death. This finding indicates that ubiquitination of cFLIP by MIB2 plays an essential role in suppressing caspase 8-mediated cell death, suggesting that ubiquitination of cFLIP may be a promising target for development of therapies to control cell death. (2021-01-27)

Researchers identify genetic dependencies in tumors that have undergone whole genome doubling
Researchers from Boston University School of Medicine (BUSM) have identified proteins that are essential for the viability of whole genome doubled tumor cells, yet non-essential to normal cells that comprise the majority of human tissue. (2021-01-27)

Myeloid immune cells in the blood tied to severe COVID-19
Individual variations in how the immune system responds to SARS-CoV-2 appear to impact the severity of disease. Researchers at Karolinska Institutet in Sweden have now been able to show that patients with severe COVID-19 have significantly elevated levels of a certain type of immune cells in their blood, called myeloid-derived suppressor cells. The study published in the Journal of Clinical Investigation may bring an increased understanding of how early immune responses impact disease severity. (2021-01-26)

Oncotarget: Improved therapeutic efficacy of unmodified anti-tumor antibodies
The Oncotarget findings suggest that MEKi induced an increased expression of tumor-associated antigens, which in combination with anti-tumor antibodies, generated a robust adaptive anti-tumor response that was sustained by immune checkpoint inhibition therapy. (2021-01-25)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.